Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We aimed to characterize the role of HMGB1 overexpression in glioma and to evaluate its use as a biomarker. We used the gene expression datasets and tissue microarray to assess the expression levels of HMGB1 among gliomas of all grades; We then assessed its correlation with the malignancy and outcome of glioma. The increase in HMGB1 mRNA and protein levels was found in glioma, but there was no correlation between HMGB1 expression and glioma malignancy, and overall survival and vital status of glioma patients. Overexpression of HMGB1 is not associated with the malignancy and outcome in glioma. And it is not the valuable biomarker for the early diagnosis of glioma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/bmm-2019-0031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demethoxycurcumin induces apoptosis and reduces cell migration by affecting AKT/mTOR-dependent autophagy in human glioma U87MG and T98G cell lines.
Mol Biol Rep
September 2025
Dr. B. R. Ambedkar Centre for Biomedical Research North Campus , University of Delhi, 110007, Delhi, India.
Background: Standard treatment for glioblastoma includes chemotherapy, alkylating agents such as temozolomide (TMZ); however, MGMT resistance leads to recurrence. Demethoxycurcumin (DMC) has been reported to inhibit cancer cell growth, induce apoptosis, and prevent metastasis in different cancer models. We investigated the DMC-induced apoptosis and autophagy via inhibition of the AKT/mTOR pathway in human glioma U87MG and T98G cell lines.
View Article and Find Full Text PDFAdvancing Targeted Drug Delivery in Glioblastoma Multiforme Through Biomimetic Nanomedicine Using 3D Tumor-On-a-Chip Model.
Adv Healthc Mater
September 2025
School of Biological and Health Systems Engineering (SBHSE), Arizona State University, Tempe, AZ, 85287, USA.
The prognosis of glioblastoma multiforme (GBM) remains dismal, despite standard treatment regimens. A key challenge in treating GBM is the persistence of glioma stem cells (GSCs) within the perivascular niche (PVN) - a protective tumor microenvironment (TME) that is often associated with inadequate drug penetration. Current preclinical models do not capture complexity of the human TME, particularly the vasculature and niche-specific interactions that drive GBM progression.
View Article and Find Full Text PDFAltered effective connectivity in leucine-rich glioma-inactivated 1 antibody encephalitis: a spectral dynamic causal modeling study.
Psychoradiology
August 2025
Department of Radiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Background: Despite advances in understanding the effective connectivity (EC) of brain networks in leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis, the specific cause and underlying mechanisms of LGI1 encephalitis remain unclear.
Materials And Methods: The study included 27 patients with anti-LGI1 encephalitis and 28 age- and sex-matched normal controls. Amplitude of low-frequency fluctuation (ALFF) analysis identified altered brain regions.
Advances and challenges in novel drug delivery systems for glioma therapy.
Front Pharmacol
August 2025
Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Glioma therapy faces substantial challenges primarily due to the restrictive nature of the blood-brain barrier (BBB), limiting effective drug penetration and reducing therapeutic efficacy. Recent advancements in novel drug delivery systems (DDS), including exosome-mediated carriers, drug conjugates, and ultrasound-assisted delivery, have demonstrated promising results in overcoming these limitations. Exosomes offer superior biocompatibility, efficient BBB crossing, and natural cellular targeting capabilities; drug conjugates enable highly selective drug delivery through tumor-specific ligands; and ultrasound-assisted systems transiently disrupt the BBB to permit greater drug entry.
View Article and Find Full Text PDFAstrocytes, the predominant glial cells in the central nervous system (CNS), play a pivotal role in maintaining neuronal homeostasis and function. Accumulating evidence suggests that astrocytic dysfunction is closely associated with the pathogenesis of various neurological disorders, including neurodegenerative diseases, ischemic stroke (IS), epilepsy, and glioma. Lipid droplets (LDs), ubiquitous intracellular lipid storage organelles, exhibit metabolic abnormalities that are commonly observed in these neurological conditions, particularly in astrocytes, where LD metabolic dysregulation may serve as a critical link between glial dysfunction and neuronal damage.
View Article and Find Full Text PDF